Home

Free report · 41 pages · PDF · November 2026

AI-driven customer engagement

The future of pharma commercialization

More health professionals and patients now use AI to look up medicines: 72% of US doctors used AI for at least one task in 2026, up from 38% in 2023, and 32% of US adults used an AI chatbot for health. The report shows where AI appears when a medicine is chosen, and estimates the cost of a team supported by AI agents.

Cover of the report AI-driven customer engagement: the future of pharma commercialization

In the report

  • 3 changes in how medicines are sold, with the evidence for each
  • Where AI appears when a medicine is chosen, and its known limits
  • The estimated cost of a team supported by AI agents, in a low, a main and a high case

The publication is written in English.

Key findings

  • US doctors' use of AI rose from 38% in 2023 to 72% in 2026. Measured AMA survey of US doctors, Jan. to Feb. 2026
  • 51.9% of questions to OpenEvidence, an AI tool for doctors, were about a decision for a patient. Measured JAMA study of OpenEvidence questions, 2024 to 2026
  • 32% of US adults used an AI chatbot for health, up from 16% a year earlier. Measured Rock Health survey of 8,000 US adults, Dec. 2025
  • Brands over 10 years old receive about 1.5% of their sales in promotion. Estimated IQVIA, 2026
  • A team shared across brands and supported by AI agents costs an estimated 64.4% less per brand in the main case, and 2.6% less at worst. Estimated aikka cost model, report p. 26

Exhibits

Chart of US adults who used an AI chatbot for health information or advice in December 2025, by generation: millennials 48%, Gen Z 45%, all US adults 32%, Gen X 25%, boomers 12%. All US adults were at 16% a year earlier.
Exhibit 6 of the report (p. 10). 48% of US millennials used AI for health; 12% of boomers. Source: Rock Health survey of 8,000 US adults, Dec. 2025. Measured.
The patient's path in 6 steps, with 2 decision steps. Choice of treatment: 51.9% of all questions to OpenEvidence concerned a clinical decision; 33.1% of doctors' questions concerned treatment; about two thirds of health professionals' questions that name a prescription medicine concern a specific clinical decision. Insurance approval: 19% of 150 US insurers, care providers and health service firms used AI agents; 75% of insurance coverage checks ran automatically in the Epic and Humana pilot; up to 90% of requests can be approved automatically, according to Cohere Health (company claim, not observed).
Exhibit 17 of the report (p. 22). AI already helps when a medicine is chosen and when it is approved. Source: JAMA, IQVIA, McKinsey, Bain and KLAS, Cohere Health, 2025 to 2026. Measured.
Range chart of the estimated yearly cost per brand in the US. Team of sales reps: low $6.79M, main $11.18M, high $17.12M. Team supported by AI agents: low $2.08M, main $3.98M, high $6.62M. Even the highest estimate for the AI team is below the lowest for the sales rep team.
Exhibit 23 of the report (p. 26). Estimated cost is 64.4% lower in the main case and 2.6% at worst. Source: aikka estimate, 2026. Estimated.

aikka SAS (Paris) uses your details to send you this report and, if you ticked the box, our future research. Your form is processed by Formspree (USA, EU Standard Contractual Clauses). We keep your details for 36 months after our last exchange. You can access, correct or delete them, or object, at admin@aikka.ai. Details in our privacy notice.

aikka builds AI-native commercialization for pharma. PharmaGEO, our entry product, shows brand teams what health professionals and patients ask AI tools about their medicines, and what the AI tools answer.

  • Legal notice
  • Terms of use
  • Cookies
  • Privacy
  • Security
  • Support
  • Documentation
  • Release notes
  • Service status

© 2026 Aikka. All rights reserved.

Log in
LinkedIn ↗